Cheng AL - Search Results

1

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Yau T, et al. Among authors: cheng al. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13. Lancet Oncol. 2022. PMID: 34914889 Clinical Trial.

2

Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy.

Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL. Hsu CH, et al. Among authors: cheng al. Oncology. 2002;62(4):305-12. doi: 10.1159/000065061. Oncology. 2002. PMID: 12138237

3

Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.

Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL. Hsu C, et al. Among authors: cheng al. Cancer. 2002 Nov 15;95(10):2044-50. doi: 10.1002/cncr.10951. Cancer. 2002. PMID: 12412156 Free article. Clinical Trial.

4

Low-dose thalidomide treatment for advanced hepatocellular carcinoma.

Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Hsu C, et al. Among authors: cheng al. Oncology. 2003;65(3):242-9. doi: 10.1159/000074477. Oncology. 2003. PMID: 14657598

5

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Lu YS, et al. Among authors: cheng al. Hepatogastroenterology. 2004 May-Jun;51(57):815-9. Hepatogastroenterology. 2004. PMID: 15143923 Clinical Trial.

6

Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.

Hsu C, Cheng JC, Cheng AL. Hsu C, et al. Among authors: cheng al, cheng jc. J Formos Med Assoc. 2004 Jul;103(7):483-95. J Formos Med Assoc. 2004. PMID: 15318270 Review.

7

Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.

Yang CH, Chen MC, Cheng AL, Hsu CH, Yeh KH, Yu YC, Whang-Peng J, Yang PC. Yang CH, et al. Among authors: cheng al. Oncology. 2005;68(4-6):350-5. doi: 10.1159/000086974. Epub 2005 Jul 11. Oncology. 2005. PMID: 16020962 Clinical Trial.

8

Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.

Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL. Yeh KH, et al. Among authors: cheng al. Oncology. 2005;69(1):88-95. doi: 10.1159/000087304. Epub 2005 Aug 2. Oncology. 2005. PMID: 16088236 Clinical Trial.

9

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Lin CC, et al. Among authors: cheng al. Invest New Drugs. 2007 Feb;25(1):77-84. doi: 10.1007/s10637-006-9004-9. Epub 2006 Aug 26. Invest New Drugs. 2007. PMID: 16937079 Clinical Trial.

10

Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.

Lin CC, Hsu CH, Hour TC, Cheng AL, Huang CY, Huang KH, Chen J, Pu YS. Lin CC, et al. Among authors: cheng al. Urol Oncol. 2007 May-Jun;25(3):207-13. doi: 10.1016/j.urolonc.2006.06.002. Urol Oncol. 2007. PMID: 17483017 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

804 results

Search Page